These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of primary cutaneous follicular centre lymphoma with rituximab: a report of two cases. Kennedy GA; Blum R; McCormack C; Prince HM Australas J Dermatol; 2004 Feb; 45(1):34-7. PubMed ID: 14961906 [TBL] [Abstract][Full Text] [Related]
4. Rituximab monotherapy for primary cutaneous B-cell lymphoma: response and follow-up in 16 patients. Valencak J; Weihsengruber F; Rappersberger K; Trautinger F; Chott A; Streubel B; Muellauer L; Der-Petrossian M; Jonak C; Binder M; Raderer M Ann Oncol; 2009 Feb; 20(2):326-30. PubMed ID: 18836086 [TBL] [Abstract][Full Text] [Related]
5. Rituximab plus liposomal pegylated doxorubicin in the treatment of primary cutaneous B-cell lymphomas. Fabbri A; Cencini E; Alterini R; Rubegni P; Rigacci L; Delfino C; Puccini B; Fimiani M; Bosi A; Bocchia M; Pimpinelli N; Eur J Haematol; 2014 Aug; 93(2):129-36. PubMed ID: 24635751 [TBL] [Abstract][Full Text] [Related]
6. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab. Bonnekoh B; Schulz M; Franke I; Gollnick H J Cancer Res Clin Oncol; 2002 Mar; 128(3):161-6. PubMed ID: 11935303 [TBL] [Abstract][Full Text] [Related]
7. Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab). Aboulafia DM Am J Clin Oncol; 2001 Jun; 24(3):237-40. PubMed ID: 11404492 [TBL] [Abstract][Full Text] [Related]
8. Remarkable remission of a follicular lymphoma treated with rituximab and polychemotherapy (CHOP). Schmook T; Stockfleth E; Lischner S; Gahn B; Christophers E; Hauschild A Clin Exp Dermatol; 2003 Jan; 28(1):31-3. PubMed ID: 12558625 [TBL] [Abstract][Full Text] [Related]
9. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy]. Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050 [TBL] [Abstract][Full Text] [Related]
10. Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Lacouture ME; Baron JM; Jani AB; Laumann AE; Soltani K Clin Exp Dermatol; 2005 Jan; 30(1):46-8. PubMed ID: 15663503 [TBL] [Abstract][Full Text] [Related]
11. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Sokol L; Naghashpour M; Glass LF Cancer Control; 2012 Jul; 19(3):236-44. PubMed ID: 22710899 [TBL] [Abstract][Full Text] [Related]
12. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Kerl K; Prins C; Saurat JH; French LE Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389 [TBL] [Abstract][Full Text] [Related]
13. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200 [TBL] [Abstract][Full Text] [Related]